Mobile

Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5126766, a dual Raf and MEK inhibitor, administered orally as monotherapy in patients w...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-002298-11

Open-label, multicenter, dose-escalation Phase I/II study to evaluate safety, pharmacokinetics and activity of RO5126766, a dual Raf and MEK inhibitor, administered orally as monotherapy in patients with advanced tumors

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Part I of the study (Dose Escalation): - To determine the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLT) of RO5126766 administered on an oral continuous daily schedule. Part II of the study (Expansion Cohort): - To investigate RO5126766 single agent activity in patients with metastatic or advanced solid tumor.

Critère d'inclusion

  • To investigate RO5126766 single agent activity in patients with metastatic or advanced solid tumor

Liens